Anthem Biosciences Ltd
Fri 29/08/2025,15:59:32 | NSE : ANTHEM
Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.
Market Data
Essential tool: analyze, trade, manage, decide.
Open
₹ 820.90
Previous Close
₹ 817.50
Volume
665988
Mkt Cap ( Rs. Cr)
₹45942.51
High
₹ 837.50
Low
₹ 816.10
52 Week High
₹ 864.90
52 Week Low
₹ 701.90
Book Value Per Share
₹ 42.92
Dividend Yield
0.00
Face Value
₹ 2.00
What’s Your Call?
Collective community sentiment on Anthem Biosciences Ltd
Your Vote -
Buy
33.33%
Hold
33.33%
Sell
33.33%
33.33%
3 users have voted
Market Depth
How many stocks are available to buy or sell and at what prices.
Buy Order Quantity
100%
Sell Order Quantity
0%
Bid Price
Qty
818.05
5111
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
5111
Bid Price
Qty
0.00
0
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
0
Option Chain
Analyzes market sentiment, predicts Anthem Biosciences Ltd' movement.
NO_RECORD_FOUND
News
Media spotlight triggers stock stock attention, sentiment.
-
Anthem Biosciences - Analysts/Institutional Investor Meet/Con. Call Updates
-
Anthem Biosciences Q1 net profit jumps 73.82% at Rs 148.34 cr
-
Anthem Biosciences - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
-
Anthem Biosciences - Copy of Newspaper Publication
-
Anthem Biosciences - Copy of Newspaper Publication
-
Anthem Biosciences - Analysts/Institutional Investor Meet/Con. Call Updates
-
Anthem Biosciences - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
-
Anthem Biosciences - Shareholders meeting
-
Anthem Biosciences - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
-
Anthem Biosciences - Press Release
-
Anthem Biosciences - Investor Presentation
-
Anthem Biosciences - Announcement under Regulation 30 (LODR)-Investor Presentation
-
Anthem Biosciences - Announcement under Regulation 30 (LODR)-Press Release / Media Release
-
Anthem Biosciences - Outcome Of Board Meeting Held On Wednesday, August 13, 2025
-
Anthem Biosciences - Outcome of Board Meeting
-
Anthem Biosciences - Board Meeting Outcome for Outcome Of Board Meeting Held On Wednesday, August 13, 2025
-
Anthem Biosciences - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
-
Anthem Biosciences - Analysts/Institutional Investor Meet/Con. Call Updates
-
Anthem Biosciences - Board Meeting Intimation for Considering And Approval Of The Unaudited Financial Results For The Quarter
-
Anthem Biosciences Ltd. debuts with 26.85% premium at Rs 723.10
-
Anthem Biosciences Ltd. debuts with 26.85% premium at Rs 723.10
-
Anthem Biosciences Ltd. debuts with 26.85% premium at Rs 723.10
-
Anthem Biosciences Ltd. debuts with 26.85% premium at Rs 723.10
-
Anthem Biosciences Ltd. debuts with 26.85% premium at Rs 723.10
-
Anthem Biosciences Ltd. debuts with 26.85% premium at Rs 723.10
-
Anthem Biosciences Ltd. debuts with 26.85% premium at Rs 723.10
-
Anthem Biosciences Ltd. debuts with 26.85% premium at Rs 723.10
-
Anthem Biosciences Ltd. debuts with 26.85% premium at Rs 723.10
-
Anthem Biosciences Ltd. debuts with 26.85% premium at Rs 723.10
-
Anthem Biosciences Ltd. debuts with 26.85% premium at Rs 723.10
-
Anthem Biosciences Ltd. debuts with 26.85% premium at Rs 723.10
-
Anthem Biosciences Ltd. debuts with 26.85% premium at Rs 723.10
-
Anthem Biosciences Ltd. debuts with 26.85% premium at Rs 723.10
-
Anthem Biosciences Ltd. debuts with 26.85% premium at Rs 723.10
-
Anthem Biosciences Ltd. debuts with 26.85% premium at Rs 723.10
-
Anthem Biosciences Ltd. debuts with 26.85% premium at Rs 723.10
-
Anthem Biosciences Ltd. debuts with 26.85% premium at Rs 723.10
-
Anthem Biosciences Ltd. debuts with 26.85% premium at Rs 723.10
-
Anthem Biosciences Ltd. debuts with 26.85% premium at Rs 723.10
-
Anthem Biosciences Ltd. debuts with 26.85% premium at Rs 723.10
-
Anthem Biosciences Ltd. debuts with 26.85% premium at Rs 723.10
-
Anthem Biosciences Ltd. debuts with 26.85% premium at Rs 723.10
-
Anthem Biosciences Ltd. debuts with 26.85% premium at Rs 723.10
-
Anthem Biosciences Ltd. debuts with 26.85% premium at Rs 723.10
-
Anthem Biosciences Ltd. debuts with 26.85% premium at Rs 723.10
-
Anthem Biosciences Ltd. debuts with 26.85% premium at Rs 723.10
-
Anthem Biosciences Ltd. debuts with 26.85% premium at Rs 723.10
-
Anthem Biosciences Ltd. debuts with 26.85% premium at Rs 723.10
-
Anthem Biosciences Ltd. debuts with 26.85% premium at Rs 723.10
-
Anthem Biosciences has submitted to BSE the Shareholding Pattern for the Period Ended July 18, 2025
-
Anthem Biosciences Ltd. debuts with 26.85% premium at Rs 723.10
-
Anthem Biosciences - Updates
-
Anthem Biosciences - Updates
-
Anthem Biosciences - Updates
-
Anthem Biosciences - Updates
-
Anthem Biosciences - Trading Window
-
Anthem Biosciences - Intimation Under Regulation 30(5) Of The Securities And Exchange Board Of India (Listing Obligation And
-
Anthem Biosciences - Announcement Under Regulation 7(1) Of The Securities And Exchange Board Of India (Listing Obligation And
-
Anthem Biosciences - Appointment of Company Secretary and Compliance Officer
-
Anthem Biosciences Ltd. debuts with 26.85% premium at Rs 723.10
-
Anthem Biosciences Ltd. debuts with 26.85% premium at Rs 723.10
-
Anthem Biosciences Ltd. debuts with 26.85% premium at Rs 723.10
-
Anthem Biosciences announces launch of initial public offering
Key fundamentals
Evaluate the intrinsic value of Anthem Biosciences Ltd stock
Name | March-25 | March-24 | March-23 | March-22 | |
---|---|---|---|---|---|
Assets | 2582.167 | 2099.6616 | 1855.5501 | 1390.9533 | |
Liabilities | 2582.167 | 2099.6616 | 1855.5501 | 1390.9533 | |
Equity | 111.8154 | 111.8154 | 114.0974 | 8.7763 | |
Gross Profit | 689.01 | 504.8861 | 429.0579 | 565.4535 | |
Net Profit | 506.1875 | 374.7807 | 385.6711 | 405.9902 | |
Cash From Operating Activities | 439.8357 | 164.4076 | 318.9833 | 333.3458 | |
NPM(%) | 27.5 | 26.43 | 36.48 | 32.97 | |
Revenue | 1840.6491 | 1417.539 | 1056.9243 | 1231.256 | |
Expenses | 1151.6391 | 912.6529 | 627.8664 | 665.8025 | |
ROE(%) | 21 | 15.54 | 16 | 16.84 |
Corporate Action
XD-Date | Dividend-Amount | Dividend-% | Dividend Yield(%GE) | Price on that day |
---|
Peers
Other companies within the same industry or sector that are comparable to Anthem Biosciences Ltd
Company | Price | Price (% change) | pe(x) | EV/EBITDA(x) | ROE(%) | ROCE(%) |
---|---|---|---|---|---|---|
Sharda Cropchem Ltd | 949.10 | 1.51 | 20.39 | 7385.00 | 337.37 | 0.95 |
Amines and Plasticizers Ltd | 220.92 | 0.89 | 30.56 | 4503.66 | 372.61 | 0.23 |
Indogulf Cropsciences Ltd | 105.57 | -1.13 | 0.00 | 1925.12 | 49.78 | 0.00 |
Grauer and Weil (India) Ltd | 115.60 | 0.00 | 34.92 | 37114.04 | 346.70 | 0.43 |
Company Info
Our Company was originally incorporated as "Anthem Biosciences Private Limited" under the provisions of the Companies Act, 1956, pursuant to a certificate of incorporation dated June 13, 2006, issued by RoC. Subsequently, our Company was converted from a private company to a public company, pursuant to a board resolution dated October 18, 2024 and a resolution passed in the extraordinary general meeting of our Shareholders held on October 18, 2024 following which the name of our Company was changed to "Anthem Biosciences Limited" and a certificate of incorporation consequent upon conversion to public limited company was issued by the RoC on December 10, 2024.Major Events and Milestones:2006- Incorporation of our Company.2007- Commenced operations of our Company at Unit I and set up a custom synthesis plant with a capacity of 6 KL.2008- Commencement of the discovery biology services with a fermentation capacity of 2 KL.2010- Expanded the custom synthesis plant set up at Unit I increasing its capacity from 6 KL to 24 KL.2013- Received the first USFDA audit approval for Unit I.2016- Set up a high potent lab at Unit I - Bommasandra Facility.2017- Our Company, pursuant to an order dated November 30, 2017, amalgamated with Anthem Cellutions (India) Private Limited by way of an acquisition of 100% of its share capital.- Set up a solid phase peptide synthesis GMP lab with a capacity of 6 KL at Unit 1.- Commenced operations of our Company at Unit II and set up an automated GMP compliant custom synthesis plant with a capacity of 128 KL and a fermentation plant with a capacity of 80 KL.- Received the second USFDA audit approval for Unit I.2018- Anthem Cellutions (India) Private Limited amalgamated into our Company.2019- Received the third USFDA approval for Unit I.- Set up a flow chemistry lab at Unit I.2020- Commenced operations in biological facility 2 earmarked for a specific client.2022- Expanded the custom synthesis plant set up at Unit II increasing its capacity to 246 KL.2023- Received the first USFDA audit approval and first therapeutic goods administration audit for Unit II.- Addition of Oligonucleotide lab in Unit I.- Set a cGMP scale continuous flow manufacturing facility for Unit II.2024- Received the: second USFDA audit approval for Unit II; first ANVISA audit approval for Unit I(1); and first ANVISA audit approval for Unit II(1).- Commenced operations of Neoanthem Lifesciences Private Limited, at Unit III designed as a chemistry lab and customer synthesis pilot plant for development, technology transfer and scale-up projects.- Fermentation capacity expanded to 140 KL at Unit II.- Conversion of our Company into a public limited company, under the name "Anthem Biosciences Limited".2025- Received the fourth USFDA approval for Unit I.
Our Company was originally incorporated as "Anthem Biosciences Private Limited" under the provisions of the Companies Act, 1956, pursuant to a certificate of incorporation dated June 13, 2006, issued by RoC. Subsequently, our Company was converted from a private company to a public company, pursuant to a board resolution dated October 18, 2024 and a resolution passed in the extraordinary general meeting of our Shareholders held on October 18, 2024 following which the name of our Company was changed to "Anthem Biosciences Limited" and a certificate of incorporation consequent upon conversion to public limited company was issued by the RoC on December 10, 2024.Major Events and Milestones:2006- Incorporation of our Company.2007- Commenced operations of our Company at Unit I and set up a custom synthesis plant with a capacity of 6 KL.2008- Commencement of the discovery biology services with a fermentation capacity of 2 KL.2010- Expanded the custom synthesis plant set up at Unit I increasing its capacity from 6 KL to 24 KL.2013- Received the first USFDA audit approval for Unit I.2016- Set up a high potent lab at Unit I - Bommasandra Facility.2017- Our Company, pursuant to an order dated November 30, 2017, amalgamated with Anthem Cellutions (India) Private Limited by way of an acquisition of 100% of its share capital.- Set up a solid phase peptide synthesis GMP lab with a capacity of 6 KL at Unit 1.- Commenced operations of our Company at Unit II and set up an automated GMP compliant custom synthesis plant with a capacity of 128 KL and a fermentation plant with a capacity of 80 KL.- Received the second USFDA audit approval for Unit I.2018- Anthem Cellutions (India) Private Limited amalgamated into our Company.2019- Received the third USFDA approval for Unit I.- Set up a flow chemistry lab at Unit I.2020- Commenced operations in biological facility 2 earmarked for a specific client.2022- Expanded the custom synthesis plant set up at Unit II increasing its capacity to 246 KL.2023- Received the first USFDA audit approval and first therapeutic goods administration audit for Unit II.- Addition of Oligonucleotide lab in Unit I.- Set a cGMP scale continuous flow manufacturing facility for Unit II.2024- Received the: second USFDA audit approval for Unit II; first ANVISA audit approval for Unit I(1); and first ANVISA audit approval for Unit II(1).- Commenced operations of Neoanthem Lifesciences Private Limited, at Unit III designed as a chemistry lab and customer synthesis pilot plant for development, technology transfer and scale-up projects.- Fermentation capacity expanded to 140 KL at Unit II.- Conversion of our Company into a public limited company, under the name "Anthem Biosciences Limited".2025- Received the fourth USFDA approval for Unit I.
Read More
Parent Organisation
Anthem Biosciences Ltd.
Founded
13/06/2006
Managing Director
NSE Symbol
ANTHEMEQ
FAQ
The current price of Anthem Biosciences Ltd is ₹ 818.05.
The 52-week high for Anthem Biosciences Ltd is ₹ 837.50 and the 52-week low is ₹ 816.10.
The market capitalization of Anthem Biosciences Ltd is currently ₹ 45942.51. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.
To buy Anthem Biosciences Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.
To invest in Anthem Biosciences Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Anthem Biosciences Ltd shares.
The CEO of Anthem Biosciences Ltd is , who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.